Adnan Khan, MD
Neurology · Manchester, NHNPI 1649539172
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.4% of the total across 229 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by AbbVie at 34.7% of the total. Reporting peaked in 2021 at $1,313 and has fallen 84.1% since, to $208 in 2025.
Across 229 payments — averaging $14.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Teva Pharmaceuticals USA, Inc.$279
- Biohaven Pharmaceuticals, Inc.$241
- Sanofi$219
- Novartis$148
- Avanir Pharmaceuticals, Inc.$135
- plus $1K from 26 others
What the payments were for
- Food & beverage$3,21797%
- Education$873%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 92 | $1,145 |
| Teva Pharmaceuticals USA, Inc. | 10 | $279 |
| Biohaven Pharmaceuticals, Inc. | 34 | $241 |
| Sanofi | 12 | $219 |
| Novartis | 7 | $148 |
| Avanir Pharmaceuticals, Inc. | 10 | $135 |
| Eisai Inc. | 5 | $99 |
| Jazz Pharmaceuticals Inc. | 5 | $92 |
| Supernus Pharmaceuticals, Inc. | 7 | $90 |
| Ironshore Pharmaceuticals Inc. | 1 | $88 |
| Corium, LLC | 1 | $73 |
| Amgen | 3 | $71 |
| Sunovion Pharmaceuticals Inc. | 7 | $59 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $54 |
| Neurocrine Biosciences, Inc. | 2 | $50 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Lundbeck LLC | 2 | $39 |
| GE HealthCare | 2 | $38 |
| Shire North American Group Inc | 3 | $38 |
| Neos Therapeutics, LP | 2 | $37 |
| UCB, Inc. | 2 | $34 |
| Biogen | 2 | $33 |
| Bausch Health US, LLC | 2 | $32 |
| Arbor Pharmaceuticals, Inc. | 2 | $27 |
| Adlon Therapeutics L.p. | 2 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $26 |
| AstraZeneca | 1 | $20 |
| Livanova USA, Inc. | 1 | $14 |
| Tris Pharma Inc | 1 | $14 |
| Merck | 1 | $14 |
| Johnson & Johnson | 1 | $12 |
| Almatica Pharma LLC | 1 | $12 |
How this compares
$3,304 in reported general payments places this provider in the 80th percentile of 92 neurology providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CopaxoneGlatiramer Acetate | 14 | $79,235 |
| Emgality PenGalcanezumab-Gnlm | 18 | $13,919 |
| Aimovig AutoinjectorErenumab-Aooe | 18 | $13,805 |
| Gabapentin | 376 | $5,600 |
| Levetiracetam | 92 | $4,470 |
| Memantine Hcl | 151 | $4,205 |
| Carbamazepine ErCarbamazepine | 25 | $3,158 |
| Duloxetine Hcl | 57 | $1,808 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 46 | $1,689 |
| Lamotrigine | 29 | $1,220 |
| Phenytoin Sodium Extended | 36 | $1,083 |
| Pregabalin | 40 | $1,054 |
| Carbamazepine | 18 | $985 |
| Topiramate | 105 | $915 |
| Lacosamide | 24 | $880 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Copaxone | $279 | $79,23514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 92 neurology providers in New Hampshire.
Other neurology in Manchester
- Ann CabotManchester$622K
- Emilia RaimondoManchester$791
- Jing JiManchester$500
- Jason FlemingManchester$495
- Anas HannounManchester$414
- Ana LizamaManchester$326
- Xiao Qing WangManchester$306
- Elena IvashinaManchester$301
- Keith McAvoyManchester$236
- Oliver PhillipsLebanon$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.